Clinical Trial Update: Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of Ecopipam for self-injurious behavior in Lesch-Nyhan disease was terminated; results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lesch-nyhan Disease
• Self-injurious Behavior

Drugs mentioned

• Ecopipam (Ecopipam)

Snippet

Sponsor: Emalex Biosciences Inc. | Conditions: Lesch-Nyhan Disease, Self-injurious Behavior | Phase 3 | Status: TERMINATED | Results posted: 2015-10-08